Evotec AG (NASDAQ:EVO - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $3.82, but opened at $4.00. Evotec shares last traded at $4.03, with a volume of 58,787 shares.
Analysts Set New Price Targets
A number of research analysts have issued reports on the stock. Royal Bank Of Canada restated an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $5.93.
Read Our Latest Analysis on EVO
Evotec Price Performance
The company has a current ratio of 2.03, a quick ratio of 1.93 and a debt-to-equity ratio of 0.46. The stock has a 50-day moving average price of $4.11 and a 200-day moving average price of $4.00.
Hedge Funds Weigh In On Evotec
Large investors have recently modified their holdings of the stock. DCF Advisers LLC increased its stake in Evotec by 227.0% in the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after buying an additional 521,708 shares in the last quarter. ABC Arbitrage SA bought a new stake in Evotec during the 1st quarter valued at about $260,000. Lighthouse Investment Partners LLC bought a new stake in shares of Evotec during the fourth quarter valued at approximately $166,000. UMB Bank n.a. bought a new stake in shares of Evotec in the 2nd quarter valued at about $56,000. Finally, Bank of America Corp DE raised its holdings in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
